Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Novo Nordisk files annual report with the SEC | ||||||||||||||
By: GlobeNewswire - 31 Jan 2024 | Back to overview list |
|||||||||||||
Bagsværd, Denmark, 31 January 2024 – Novo Nordisk A/S has filed its Annual Report 2023 on Form 20-F for the financial year 2023 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2023. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Shareholders may receive a hard copy of Novo Nordisk’s completed audited financial statements free of charge upon request to ancx@novonordisk.com. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. Contact for further information
Attachment |
||||||||||||||
|
||||||||||||||
Copyright 2024 GlobeNewswire | Back to overview list |